Story thread · 3 reports / 3 sources
Seattle biotech BrainChild Bio raises $116M to advance CAR T therapy for childhood brain cancer
geekwire.com · 4d
How the coverage leans
Across 3 sources · syndicated copies counted once
Seattle biotech BrainChild Bio has raised $116 million to advance an experimental CAR T cell therapy for DIPG, a rare and deadly brain tumor that primarily affects young children. The company is building on technology developed at Seattle Children’s and is also developing CAR T therapies for other pediatric and adult brain tumors. Read More
First report: BrainChild hauls in $116M to make cell therapies for childhood brain cancers — biopharmadive.com, 6d
The coverage
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.